NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free ARCT Stock Alerts $33.75 +0.89 (+2.71%) (As of 03:04 PM ET) Add Compare Share Share Today's Range$32.00▼$33.7550-Day Range$31.72▼$42.9952-Week Range$17.52▼$43.81Volume200,803 shsAverage Volume437,919 shsMarket Capitalization$908.55 millionP/E RatioN/ADividend YieldN/APrice Target$57.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Arcturus Therapeutics alerts: Email Address Arcturus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside72.8% Upside$57.71 Price TargetShort InterestBearish17.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 14 Articles This WeekInsider TradingSelling Shares$910,434 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.42) to $5.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 starsMedical Sector540th out of 938 stocksPharmaceutical Preparations Industry251st out of 433 stocks 3.5 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $57.71, Arcturus Therapeutics has a forecasted upside of 72.8% from its current price of $33.39.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.16% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 0.24%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 3.1 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Arcturus Therapeutics this week, compared to 3 articles on an average week.Search Interest15 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows10 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $910,434.00 in company stock.Percentage Held by Insiders13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($1.42) to $5.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -32.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -32.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Arcturus Therapeutics Stock (NASDAQ:ARCT)Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More ARCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARCT Stock News HeadlinesMarch 28, 2024 | insidertrades.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells $610,573.70 in StockMarch 22, 2024 | insidertrades.comInsider Selling: Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells 8,565 Shares of StockMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 28, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) Insider Sells SharesMarch 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in JapanMarch 25, 2024 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Buy" from AnalystsMarch 23, 2024 | americanbankingnews.comPad Chivukula Sells 8,565 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) StockMarch 22, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...March 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 21, 2024 | americanbankingnews.comArcturus Therapeutics (NASDAQ:ARCT) Stock Rating Reaffirmed by HC WainwrightMarch 17, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 16, 2024 | ca.finance.yahoo.comARCT Apr 2024 30.000 callMarch 11, 2024 | markets.businessinsider.comThe Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 ExpertsMarch 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)March 9, 2024 | seekingalpha.comArcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cigna (CI) and Arcturus Therapeutics (ARCT)March 8, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comQ4 2023 Arcturus Therapeutics Holdings Inc Earnings CallMarch 8, 2024 | finance.yahoo.comArcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline DevelopmentsMarch 7, 2024 | investorplace.comARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023March 7, 2024 | benzinga.comRecap: Arcturus Therapeutics Q4 EarningsMarch 7, 2024 | businesswire.comArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline ProgressMarch 7, 2024 | finance.yahoo.comARCT Sep 2024 30.000 putMarch 6, 2024 | benzinga.comEarnings Preview: Arcturus TherapeuticsMarch 6, 2024 | markets.businessinsider.comHere's what Wall Street expects from Arcturus Therapeutics's earningsMarch 6, 2024 | msn.comArcturus Therapeutics Q4 2023 Earnings PreviewMarch 2, 2024 | investing.comArcturus Therapeutics Holdings Inc (ARCT)See More Headlines Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$57.71 High Stock Price Target$90.00 Low Stock Price Target$36.00 Potential Upside/Downside+79.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-15.65% Pretax Margin-16.72% Return on Equity-18.22% Return on Assets-11.95% Debt Debt-to-Equity RatioN/A Current Ratio4.72 Quick Ratio4.72 Sales & Book Value Annual Sales$169.93 million Price / Sales5.10 Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book3.09Miscellaneous Outstanding Shares26,920,000Free Float23,201,000Market Cap$867.09 million OptionableOptionable Beta2.64 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Joseph E. Payne M.Sc. (Age 52)Founder, President, CEO & Director Comp: $1.13MMr. Andrew H. Sassine MBA (Age 60)CFO & Director Comp: $826.88kMs. Neda SafarzadehVice President and Head of IR/PR & MarketingMr. Lance KurataChief Legal OfficerMs. Natash O. BowmanChief Human Resources OfficerMr. Kevin T. SkolChief Business OfficerDr. Juergen Froehlich FCPh (Age 68)M.D., MBA, Chief Medical Officer Dr. Igor Smolenov M.D.Ph.D., Chief Development OfficerMore ExecutivesKey CompetitorsCassava SciencesNASDAQ:SAVAPliant TherapeuticsNASDAQ:PLRXTyra BiosciencesNASDAQ:TYRAMacroGenicsNASDAQ:MGNXArcutis BiotherapeuticsNASDAQ:ARQTView All CompetitorsInsiders & InstitutionsPad ChivukulaSold 17,435 sharesTotal: $610,573.70 ($35.02/share)Pad ChivukulaSold 8,565 sharesTotal: $299,860.65 ($35.01/share)Vanguard Group Inc.Bought 51,537 shares on 3/11/2024Ownership: 5.458%Wellington Management Group LLPBought 17,491 shares on 3/5/2024Ownership: 0.228%Goldman Sachs Group Inc.Bought 69,156 shares on 3/1/2024Ownership: 1.552%View All Insider TransactionsView All Institutional Transactions ARCT Stock Analysis - Frequently Asked Questions Should I buy or sell Arcturus Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARCT shares. View ARCT analyst ratings or view top-rated stocks. What is Arcturus Therapeutics' stock price target for 2024? 7 analysts have issued twelve-month price objectives for Arcturus Therapeutics' shares. Their ARCT share price targets range from $36.00 to $90.00. On average, they predict the company's share price to reach $57.71 in the next year. This suggests a possible upside of 72.8% from the stock's current price. View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts. How have ARCT shares performed in 2024? Arcturus Therapeutics' stock was trading at $31.53 at the beginning of the year. Since then, ARCT stock has increased by 5.9% and is now trading at $33.39. View the best growth stocks for 2024 here. When is Arcturus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ARCT earnings forecast. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.40) by $0.65. The biotechnology company earned $2.44 million during the quarter, compared to the consensus estimate of $26.70 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative trailing twelve-month return on equity of 18.22%. During the same period in the previous year, the business earned ($0.92) EPS. What ETFs hold Arcturus Therapeutics' stock? ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Morningstar US Small Growth (MSGR), Subversive Mental Health ETF (SANE), ARK Genomic Revolution ETF (ARKG), Amplify Treatments, Testing and Advancements ETF (GERM), WisdomTree BioRevolution Fund (WDNA), AXS Green Alpha ETF (NXTE), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Jacob Forward ETF (JFWD). What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.66%), Vanguard Group Inc. (5.46%), Vanguard Group Inc. (5.46%), Sumitomo Mitsui Trust Holdings Inc. (4.94%), Nikko Asset Management Americas Inc. (4.94%) and Dimensional Fund Advisors LP (4.08%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARCT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAI to Meet the Same Fate as EVs? Porter & CompanyGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.